PET分子影像在肺癌免疫检查点抑制剂治疗中的作用:精准医学与可视化监测
本文综述肺癌免疫微环境、免疫检查点抑制剂(ICI)治疗机制及应用现状,重点总结基于PET的18F-氟脱氧葡萄糖(18F-FDG)及靶向免疫检查点示踪剂在肺癌中的应用,为筛选适合ICI治疗的患者和评估疗效提供参考,并展望PET分子影像未来研究方向。
要点
- 18F-FDG PET及其他靶向免疫检查点PET示踪剂可用于筛选可能从ICI治疗中获益的肺癌患者。
- PET分子影像可用于评估肺癌ICI治疗的治疗效果。
- 本文综述了肺癌免疫微环境、ICI治疗机制及当前应用现状。
核心结论
- 基于PET的18F-FDG及靶向免疫检查点示踪剂可为筛选适合ICI治疗的肺癌患者和评估疗效提供参考。
- 本文最后提出了PET分子影像在肺癌ICI治疗中的未来研究方向及潜在应用。
研究设计与样本
- 本文为综述,总结了肺癌免疫微环境、ICI治疗机制及其当前应用现状。
- 重点聚焦18F-FDG和其他基于PET的靶向免疫检查点示踪剂在肺癌中的应用。
临床应用与阅片要点
- 18F-FDG PET及其他靶向免疫检查点PET示踪剂可用于筛选可能从ICI治疗中获益的肺癌患者。
- PET分子影像可用于评估肺癌患者ICI治疗的治疗效果。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Lung cancer is a malignant tumour originating from the bronchial epithelium or glands of the lung with high morbidity and mortality. For advanced lung cancer, the lack of effective treatment often results in poor prognosis. Immune checkpoint inhibitor (ICI) therapy, as a novel therapeutic method, upregulates immunity by blocking the negative regulation of tumours. In the clinical treatment process, not all lung cancer patients can benefit from ICI treatment. Therefore, screening patients who might potentially benefit from ICI therapy and evaluating the efficacy of ICIs has become an important part of therapy for lung cancer patients. This review has summarized the immune microenvironment of lung cancer, the mechanism of ICI therapy and its current application status. Importantly, we focused on the application of 18F-fluorodeoxyglucose (18F-FDG) and other targeted immune checkpoint tracers based on positron emission tomography (PET) for lung cancer, providing a reference for screening lung cancer candidates suitable for ICI therapy and evaluating the therapeutic effect. Finally, future research directions in PET molecular imaging and their potential application in ICI therapy for lung cancer are presented.
引用
- Yao, Zhou, Zhang, et al. The role of PET molecular imaging in immune checkpoint inhibitor therapy in lung cancer: Precision medicine and visual monitoring. Eur J Radiol. 2022. PMID: 35158214. doi:10.1016/j.ejrad.2022.110200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。